Company Overview and News

WA tech firms raise $5m

Two local tech companies have raised more than $5 million, with medical firm Proteomics International Laboratories securing $3.4 million via the exercise of options.

Proteomics International Laboratories to reveal results

Proteomics International Laboratories (ASX:PIQ) has some interesting news pending, with the ASX granting the company a trading halt to prepare.

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions

Proteomics International Laboratories (ASX:PIQ) managing director, Richard Lipscombe, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

Proteomics International Laboratories targets first sales in 2017

Proteomics International Laboratories (ASX:PIQ) is targeting first commercial sales at the calendar year end for PromarkerD, a  world leading diagnostic test for diabetic kidney disease.

Dimerix brings Phase II clinical trials to Proactive's Spotlight CEO Sessions

Dimerix (ASX:DXB) is a clinical stage biotechnology company, with a focus on Phase II clinical trials for chronic kidney disease.

Proteomics International to outline pathway to market at Proactive's CEO Sessions

The company continues on a path to commercialisation as it advances deals with partners in Singapore and China to bring its PromarkerD, which is patented in both countries, to the Asian market.

Southern Gold brings gold production to Proactive's Spotlight CEO Sessions

Southern Gold (ASX:SAU) is an under the radar company producing gold near Kalgoorlie through ore agreements with Westgold Resources (ASX:WGX).

PromarkerD predictive diagnostics for DKD to roll-out in Asia

2017-03-22 biospectrumasia
It's fast, free and easy to sign in with Facebook, Google, or Yahoo. Be connected on your terms - we won't share anything without your permission

Proteomics International Laboratories to bring PromarkerD to Asia

Proteomics International Laboratories (ASX:PIQ) will advance deals with commercialisation partners in Singapore and China this week to bring PromarkerD to the Asian market.

Proteomics International Laboratories raises funds for diabetic kidney test

The directors, who were scaled back in-line with other shareholders, have committed to top up their scale-back by buying shares in the open market.

Proteomics International Laboratories Ltd to raise cash

The halt will remain in place until the opening of trade on Friday 2nd December 2016, or earlier if an announcement is made to the market.

Proteomics International Laboratories Ltd reaches milestone for test kit

The company has signed a contract with the Monash Antibody Technologies Facility to produce the custom antibodies needed for a multiplex ELISA (Enzyme-linked immunosorbent assay). This assay will be the precursor to a pathology lab in-vitro diagnostic (IVD) test. Proteomics’ shares were last trading at $0.29, up 16% intraday. The deal represents the culmination of a detailed evaluation of global manufacturing options and the required make-up of the kit's components.

Proteomics International Laboratories Ltd inks US$1.5M diagnostic test deal

Proteomics International Laboratories Ltd (ASX:PIQ) has signed an exclusive licence deal worth US$1.5 million for its PromarkerD assay used for the diagnosis of diabetic kidney disease in the Dominican Republic. PromarkerD is a specialised test that uses the unique make-up of proteins in a person’s blood to provide an early detection of the onset of diabetic kidney disease. The licence granted to Puerto Rico based Omics Global Solution will allow it to manufacture the kits in Puerto Rico and distribute in the Dominican Republic.

Proteomics International Laboratories Ltd grows revenue by 60%

Proteomics International Laboratories Ltd (ASX:PIQ) has generated monthly revenues of $100,000 in each of March and April, a 60% uplift on the previous monthly average. Several recent contract wins support ongoing activity. The company’s strategy to expand its analytical services business and in so doing, underpin its cash position. PILL's analytical services generate a regular ongoing revenue stream by providing a fee-for-service offering in life sciences.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...